GRTS Insider Trading | Gritstone bio Buys and Sells

GRTS Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 4.61%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $35,453.25

Gritstone bio Insider Trading History Chart

This chart shows the insider buying and selling history at Gritstone bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20k$0$20kTotal Insider BuyingTotal Insider Selling

Gritstone bio Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 10/21/2024 10:03 PM ET

This chart shows the closing price history over time for GRTS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Gritstone bio Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Gritstone bio (NASDAQ:GRTS)

48.46% of Gritstone bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GRTS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
Gritstone bio logo
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Read More on Gritstone bio

Today's Range

Now: N/A

50 Day Range

MA: $0.35
Low: $0.03
High: $0.63

52 Week Range

Now: N/A

Volume

61,017,902 shs

Average Volume

7,014,435 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Who are the company insiders with the largest holdings of Gritstone bio?

Gritstone bio's top insider shareholders include:
  1. Andrew R Allen (CEO)
  2. Erin Jones (COO)
  3. Matthew Hawryluk (EVP)
  4. Vassiliki Economides (Insider)
Learn More about top insider investors at Gritstone bio.